Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253994 | 0.81 | NOS1 (0.50) | NOS1KDM4ECYP3A4MEN1CYP1A2 | |
| SCHEMBL1172817 | 0.80 | NOS1 (0.49) | GAAPDPK1NOS1KDM4ECYP3A4 | |
| SCHEMBL1171722 | 0.80 | NOS1 (0.50) | GAANOS1KDM4ECYP3A4MEN1 | |
| SCHEMBL1172395 | 0.80 | NOS1 (0.49) | GAANOS1KDM4ECYP3A4MEN1 | |
| SCHEMBL1172797 | 0.80 | NOS1 (0.49) | GAANOS1MAPK8KDM4ECYP3A4 | |
| SCHEMBL9941730 | 0.80 | NOS1 (0.49) | GAANOS1KDM4ECYP3A4MEN1 | |
| SCHEMBL2721094 | 0.78 | NOS1 (0.44) | NOS1CDK2KDM4ECYP3A4MEN1 | |
| Methyl Alcohol SCHEMBL27939963 | 0.78 | NOS1 (0.46) | GAANOS1KDM4ECYP3A4MEN1 | |
| SCHEMBL29009519 | 0.78 | NOS1 (0.46) | GAANOS1AURKAAURKBKDM4E | |
| SCHEMBL2723846 | 0.76 | NOS1 (0.45) | GAANOS1MAP2K1LRRK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | claimed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | claimed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | claimed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | claimed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | claimed |
| CN-101528222-A | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | UNIV VANDERBILT (US) | 2009-09-09 | — | — | CN | claimed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | claimed |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260007783-A1 | A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer model | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250242062-A1 | ANTI-COX-2 NANOBODIES FOR ENDOSCOPIC VISUALIZATION OF COLORECTAL ADENOMAS | VANDERBILT UNIVERSITY | 2025-07-31 | — | — | US | disclosed |
| US-12370273-B2 | 3E8.scFv.Cys-IR800 conjugate targeting TAG-72 in an orthotopic colorectal cancer model | Ohio Sate Innovation Foundation (US) | 2025-07-29 | — | — | US | disclosed |
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| CN-101528222-A | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | UNIV VANDERBILT (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| US-4051252-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | GAA 1317/4885PDPK1 3432/4885NOS1 1278/4885 |
| US-20260007783-A1 | A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer model | CD74, LY96, TPD52L2 | GAA 4274/4885PDPK1 4791/4885NOS1 3853/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | GAA 1476/4885PDPK1 2819/4885NOS1 516/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | GAA 1317/4885PDPK1 3432/4885NOS1 1278/4885 |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | MUC1, CD47, CD44 | GAA 1924/4885PDPK1 4388/4885NOS1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.